238 related articles for article (PubMed ID: 31923062)
1. Relative Risk of Cervical Neoplasms Among Copper and Levonorgestrel-Releasing Intrauterine System Users.
Spotnitz ME; Natarajan K; Ryan PB; Westhoff CL
Obstet Gynecol; 2020 Feb; 135(2):319-327. PubMed ID: 31923062
[TBL] [Abstract][Full Text] [Related]
2. Safety of levonorgestrel 52 mg intrauterine system compared to copper intrauterine device: a population-based cohort study.
Bosco-Lévy P; Gouverneur A; Langlade C; Miremont G; Pariente A
Contraception; 2019 Jun; 99(6):345-349. PubMed ID: 30871933
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two cohorts of women who expulsed either a copper-intrauterine device or a levonorgestrel-releasing intrauterine system.
Simonatto P; Bahamondes MV; Fernandes A; Silveira C; Bahamondes L
J Obstet Gynaecol Res; 2016 May; 42(5):554-9. PubMed ID: 26817571
[TBL] [Abstract][Full Text] [Related]
4. Bleeding pattern difference between levonorgestrel intrauterine system and copper intrauterine devices inserted immediately post-abortion: a multicenter, prospective, observational cohort study in Chinese women.
Chen X; Li Q; Wang X; Chen J; Lv W; Shi B; Wang H; Luo J; Li J
Curr Med Res Opin; 2018 May; 34(5):873-880. PubMed ID: 29298525
[TBL] [Abstract][Full Text] [Related]
5. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
[TBL] [Abstract][Full Text] [Related]
6. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices.
Heinemann K; Reed S; Moehner S; Minh TD
Contraception; 2015 Apr; 91(4):280-3. PubMed ID: 25601350
[TBL] [Abstract][Full Text] [Related]
7. Female sexual function in women using LARC methods.
Trigo ACM; Maron CC; Pinheiro MSA; da Silva SBL; Brito MB
Gynecol Endocrinol; 2022 Jan; 38(1):68-72. PubMed ID: 34672861
[TBL] [Abstract][Full Text] [Related]
8. Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use.
Modesto W; de Nazaré Silva dos Santos P; Correia VM; Borges L; Bahamondes L
Eur J Contracept Reprod Health Care; 2015 Feb; 20(1):57-63. PubMed ID: 25160484
[TBL] [Abstract][Full Text] [Related]
9. [Weight variation in users of the levonorgestrel-releasing intrauterine system, of the copper IUD and of medroxyprogesterone acetate in Brazil].
Yela DA; Monteiro IM; Bahamondes LG; Del Castillo S; Bahamondes MV; Fernandes A
Rev Assoc Med Bras (1992); 2006; 52(1):32-6. PubMed ID: 16622536
[TBL] [Abstract][Full Text] [Related]
10. Body weight and composition in users of levonorgestrel-releasing intrauterine system.
Dal'Ava N; Bahamondes L; Bahamondes MV; de Oliveira Santos A; Monteiro I
Contraception; 2012 Oct; 86(4):350-3. PubMed ID: 22445431
[TBL] [Abstract][Full Text] [Related]
11. Selection and performance of the levonorgestrel-releasing intrauterine system.
Lähteenmäki P; Bardin CW; Elomaa K; Haukkamaa M; Kivijärvi A; Kuukankorpi A; Venhola M; Tuominen J
Acta Obstet Gynecol Scand Suppl; 1997; 164():69-74. PubMed ID: 9225643
[TBL] [Abstract][Full Text] [Related]
12. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system.
Suvisaari J; Lähteenmäki P
Contraception; 1996 Oct; 54(4):201-8. PubMed ID: 8922872
[TBL] [Abstract][Full Text] [Related]
13. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
Sturridge F; Guillebaud J
Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
[TBL] [Abstract][Full Text] [Related]
14. Safety and continued use of the levonorgestrel intrauterine system as compared with the copper intrauterine device among women living with HIV in South Africa: A randomized controlled trial.
Todd CS; Jones HE; Langwenya N; Hoover DR; Chen PL; Petro G; Myer L
PLoS Med; 2020 May; 17(5):e1003110. PubMed ID: 32442189
[TBL] [Abstract][Full Text] [Related]
15. Intrauterine device continuation rates and reasons for discontinuation in a Central European clinic with a high standard of care and ultrasound follow-up: a retrospective cohort study.
Bachofner M; Blickenstorfer K; Hutmacher J; Wehrle L; Leeners B; Merki-Feld G
Eur J Contracept Reprod Health Care; 2018 Dec; 23(6):407-414. PubMed ID: 30628516
[TBL] [Abstract][Full Text] [Related]
16. Liquid-based cervical cytology and microbiological analyses in women using cooper intrauterine device and levonorgestrel-releasing intrauterine system.
Eleuterio J; Giraldo PC; Silveira Gonçalves AK; Nunes Eleuterio RM
Eur J Obstet Gynecol Reprod Biol; 2020 Dec; 255():20-24. PubMed ID: 33065517
[TBL] [Abstract][Full Text] [Related]
17. Intrauterine contraception: incidence and factors associated with uterine perforation--a population-based study.
Kaislasuo J; Suhonen S; Gissler M; Lähteenmäki P; Heikinheimo O
Hum Reprod; 2012 Sep; 27(9):2658-63. PubMed ID: 22763376
[TBL] [Abstract][Full Text] [Related]
18. Perforation risk and intra-uterine devices: results of the EURAS-IUD 5-year extension study.
Barnett C; Moehner S; Do Minh T; Heinemann K
Eur J Contracept Reprod Health Care; 2017 Dec; 22(6):424-428. PubMed ID: 29322856
[TBL] [Abstract][Full Text] [Related]
19. Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices.
Heinemann K; Reed S; Moehner S; Minh TD
Contraception; 2015 Apr; 91(4):274-9. PubMed ID: 25601352
[TBL] [Abstract][Full Text] [Related]
20. Major differences in the characteristics of users of the copper intrauterine device or levonorgestrel intrauterine system at a clinic in Campinas, Brazil.
Laporte M; Metelus S; Ali M; Bahamondes L
Int J Gynaecol Obstet; 2022 Feb; 156(2):240-246. PubMed ID: 33872406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]